<DOC>
	<DOCNO>NCT01758367</DOCNO>
	<brief_summary>Decitabine up-regulate series immune associate protein , include cancer testis antigen ( CTA ) , major histocompatibility complex ( MHC ) , co-stimulatory molecule adhesion molecule , suggest potential benefit follow adoptive T cell therapy . In addition , decitabine induce FOXP3 expression CD4+ T cell convert CD4+ T cell T regulatory cell ( Tregs ) . As result , Graft versus host disease ( GVHD ) reduce treatment decitabine .</brief_summary>
	<brief_title>Decitabine Followed Donor Lymphocyte Infusion Patients With Relapsed Acute Myeloblastic Leukemia ( AML ) After Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<criteria>Age 18 60 year Histologically cytologically document relapse acute myeloid leukemia stem cell transplant Must ability observe efficacy event Patient must ability understand willingness provide write informed consent prior participation study relate procedure perform Must Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 3 Must suitable donor Must advance malignant hepatic tumor Must receive form chemotherapy cell infusion treatment protocol Must receive investigational agent within 14 day first dose study drug Must uncontrolled intercurrent illness include ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , psychiatric illness/social situation would limit compliance study requirement Must pregnant breastfeeding ; pregnant woman exclude study decitabine Category D agent potential teratogenic abortifacient effect ; unknown potential risk adverse event nurse infant secondary treatment mother decitabine , breastfeed discontinue mother treated decitabine ; potential risk may also apply agent use study Must history allergic reaction attribute compound similar chemical biologic composition decitabine agent use study Must know suspected hypersensitivity decitabine Must human immunodeficiency virus ( HIV ) positive combination antiretroviral therapy ; patient ineligible potential pharmacokinetic interaction decitabine ; addition , patient increase risk lethal infection treat marrowsuppressive therapy ; appropriate study undertake patient receive combination antiretroviral therapy indicate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>demethylating agent</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>decitabine ( DAC )</keyword>
	<keyword>donor lymphocyte infusion ( DLI )</keyword>
	<keyword>AML</keyword>
</DOC>